Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study hints at imaging tool to predict meningioma treatment success

NCT ID NCT06614205

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 11 patients with meningioma (a type of brain tumor) who received a treatment called 177Lu-DOTATATE. Researchers used special scans to measure how much radiation the tumors absorbed, and checked if that could predict whether patients would survive without the tumor growing for at least 6 months. The goal is to see if this imaging method can help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
177Lu-DOTATATE
What this could lead to
If successful, this could help doctors predict which patients will benefit most from 177Lu-DOTATATE treatment for meningioma.
What could go wrong
This is a very small, completed study with only 11 patients. Results may not apply to all patients, and the imaging method may not reliably predict outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

11 people

The number who actually took part.

Started

Nov 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients treated with 177Lu-DOTATATE for meningioma at Nancy University Hospital

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients treated for menigioma at nancy hospital * patients who performed 3 scintigraphics exams during there treatment Exclusion Criteria: * patients deprived of liberty * patient who refused to collect data retrospectively

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningioma of brain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intracranial meningioma meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meningioma of brain

Contacts and locations

Locations

  • CHRU de NANCY

    Vandœuvre-lès-Nancy, 54511, France

  • Nuclear medicine Department CHRU de NANCY

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.